APAP (Auto CPAP) in India: Buyer’s & Clinical Guide (2026)

An auto CPAP — clinically abbreviated APAP, sometimes written Auto-PAP or AutoCPAP — is the dominant first-line device for uncomplicated obstructive sleep apnea (OSA) in 2026. It is not a different therapy from CPAP. It is CPAP with a control loop: rather than delivering a single fixed pressure all night, the device varies pressure breath-by-breath inside a prescribed window, titrating upward when it detects flow limitation, snoring, or apnea, and titrating downward when the airway is stable.

For most patients walking out of an Indian sleep lab with a moderate-to-severe OSA diagnosis in 2026, APAP is what the prescribing physician will write. Fixed-pressure CPAP is still clinically valid in specific scenarios (covered separately in our fixed-pressure CPAP guide), but APAP is the default. This guide explains how APAP works, how the major algorithms differ, what the prescription actually looks like in Indian practice, and which machines are worth considering across the ₹17,000 to ₹1.5 lakh price spectrum the Indian market spans.

How APAP differs from fixed-pressure CPAP — in practice

A fixed-pressure CPAP delivers, say, 10 cmH₂O all night. If 10 was the titrated pressure from a lab study, the therapy works — as long as the patient’s airway behaves tonight the way it behaved during the titration night. Body position changes, alcohol intake, weight fluctuation, nasal congestion, REM concentration in the later half of the night — all shift the pressure requirement. A fixed-pressure device either delivers more pressure than needed (uncomfortable, and may trigger central events in susceptible patients) or less than needed (residual apneas).

APAP sidesteps this. The prescription specifies a minimum pressure (typically 5–7 cmH₂O) and a maximum (typically 15–20 cmH₂O), and the device runs whatever pressure is needed within that window on each breath. When flow is clean and the airway stable, pressure drops to the minimum. When the device senses the precursors of an obstructive event, pressure rises in fractions of a cmH₂O every few seconds until the event aborts.

The clinical benefit is twofold. Average nightly pressure (P95 — the pressure at or below which the patient spent 95% of the night) is typically 2–4 cmH₂O lower than a fixed-pressure titration on the same patient. This means the mask seal is easier to maintain, expiratory effort is lower, aerophagia is less common, and adherence — the single strongest determinant of long-term outcome — is meaningfully higher (AASM Practice Guidelines). Second, APAP self-corrects for conditions that would degrade fixed-pressure therapy — weight gain, positional OSA, REM-predominant events — without requiring a re-titration.

Algorithm differences that actually matter

Every APAP manufacturer says “advanced algorithm” in their brochure. The algorithms differ in three ways that the buyer needs to understand.

Event detection granularity. ResMed’s AutoSet algorithm, implemented across the AirSense 10 AutoSet, AirSense 11 AutoSet, and AirMini platforms, detects obstructive apneas, hypopneas, flow limitation, snore, and — critically — respiratory effort-related arousals (RERAs) and central apneas. When a central apnea is detected, AutoSet does not raise pressure in response; raising pressure against a central event can worsen it. The algorithm holds pressure and lets the central event resolve, which is the clinically correct response. Philips’s Auto-Trak algorithm on the DreamStation Auto family does similar central-event handling. Lower-end algorithms (BMC RESmart GII Auto, BPL Harmony Auto, Deckmount VT50) detect obstructive events but do not reliably discriminate centrals, and may therefore chase the event with a pressure rise that achieves nothing.

Response curve aggressiveness. How quickly the device raises pressure in response to flow limitation, and how quickly it returns to baseline once the airway stabilizes, varies considerably. ResMed AutoSet ramps pressure in small increments over longer time windows, which tends to produce a smoother pressure trace and fewer arousals from pressure transients. Philips DreamStation Auto is similar. More aggressive algorithms can produce higher average pressure for the same apneic load — useful if the patient has severe REM-concentrated events, less useful otherwise.

Female-specific titration. ResMed’s AutoSet for Her is a modified algorithm designed around the observation that women with OSA often present with flow-limited and RERA-predominant phenotypes rather than frank apneas. It titrates more aggressively on flow limitation and tends to deliver a slightly smoother pressure curve. It is not a marketing add-on — patients matched to the algorithm often report better tolerance. It is available on the AirSense 10 AutoSet, AirSense 11 AutoSet, and AirMini.

The Oxymed AirSmart and Oxymed SleepEasy platforms use what manufacturer brochures and e-commerce product listings describe as FlowSens technology, which includes central-apnea detection. The BMC RESmart GII Auto uses a standard-tier APAP algorithm — functional but not differentiated. The Wellel iX Auto is described in product listings as an advanced algorithm; published details are thinner than ResMed or Philips, so the buyer is reliant on manufacturer claim here.

APAP titration in India — what actually happens

In theory, an Indian sleep lab runs a diagnostic polysomnography (PSG), identifies the AHI, and brings the patient back for an in-lab CPAP titration to determine the optimal pressure. In practice, in-lab CPAP titration is available in perhaps 30–40 sleep-capable facilities in the country — concentrated in Mumbai, Delhi-NCR, Bengaluru, Chennai, Hyderabad, Pune, Kolkata, and a handful of tier-2 cities — and costs ₹8,000–₹18,000. Many patients (and many physicians) bypass the second-night titration entirely.

The realistic Indian titration pathway for an uncomplicated OSA patient in 2026 is: diagnostic PSG (either in-lab or Level-III home study, the latter now dominant), prescription for APAP with a broad window (typically 5–15 cmH₂O or 4–20 cmH₂O), then 2–4 weeks of home APAP running. The device-downloaded data — P95, AHI, mask leak, hours of use — is reviewed by the prescribing physician and the window is narrowed. This is called “auto-titration” and is the clinical reality for most patients outside the handful of high-acuity sleep centres.

For this pathway to work, the APAP needs to produce usable clinical data. ResMed AirSense 10, 11, and AirMini data are accessible via myAir (patient) and AirView (clinician). Philips DreamStation Auto data is accessible via Care Orchestrator. BMC devices record to SD card and generate compliance codes via the iCode system. The Oxymed AirSmart and SleepEasy platforms offer mobile app connectivity. Deckmount VT50 has SD-card-only data download with no cloud ecosystem. Where the prescribing physician is going to remote-review the data, the connected ResMed and Philips platforms are meaningfully easier to work with than SD-card-only devices.

When APAP is first-line, and when it isn’t

APAP is first-line for: moderate and severe OSA without significant central component; pure OSA with positional variation; REM-predominant OSA; mild OSA where CPAP has been escalated from conservative therapy; post-bariatric-surgery patients whose pressure requirement is falling; patients on weight-loss programs where the pressure requirement is a moving target.

APAP is not first-line for: confirmed central sleep apnea (needs BiPAP-ST or ASV); complex sleep apnea syndrome; obesity hypoventilation syndrome with hypercapnia (needs bilevel with volume-targeted modes — see our TVAPS guide); COPD-OSA overlap with hypercapnia; neuromuscular disease. A fixed-pressure CPAP may still be preferred in the narrow scenarios covered in our fixed-pressure CPAP guide.

For every other uncomplicated OSA presentation, APAP is the right tool.

Model-by-model: APAPs in the Indian market in 2026

Premium tier (₹45,000–₹1.5 lakh)

The ResMed AirSense 11 AutoSet is the flagship APAP in India, priced at ₹63,390 on channel listings against an MRP of ₹1,05,600. Published specs: 4–20 cmH₂O pressure range, 27 dB sound level, 1.1 kg weight, integrated HumidAir 11 heated humidifier, ClimateLineAir heated tube compatibility, touch-screen interface, Bluetooth + Wi-Fi (cellular in some regions), central-apnea detection, AutoRamp with sleep-onset detection, EPR, AutoSet and AutoSet for Her algorithms. FDA, CE, and FAA approvals per manufacturer documentation. This is the machine to buy if you want the dominant algorithm, the strongest data platform, and the strongest service network.

The ResMed AirSense 10 AutoSet is the predecessor and remains in channel at around ₹45,999. Published specs: 4–20 cmH₂O, 25 dB, 1.24 kg, heated humidifier, optional cellular connectivity. Same AutoSet and AutoSet for Her algorithms as the 11. The principal difference is the user interface (knob + LCD on the 10, touchscreen on the 11) and cloud-connectivity architecture (older SIM-based on the 10, Bluetooth-to-phone on the 11). Clinically these devices are equivalent and the 10 is a sensible buy where budget or service-network factors favour it.

The Philips DreamStation Auto BiPAP is the auto-bilevel successor platform (separate from the APAP DreamStation Auto CPAP line). The Philips DreamStation Auto CPAP platform — which sits in the APAP category — is available through Indian channels at varying price points and uses the Auto-Trak algorithm with bi-flex expiratory relief. Channel availability of DreamStation APAPs in India has been uneven since the 2021 recall and subsequent replacement program; ResMed has captured most of the premium APAP channel share in the Indian market as a direct consequence.

The Wellel iX Auto CPAP is a Taiwanese-manufactured premium-tier APAP at ₹65,280 per channel listings, though currently listed as out of stock in several Indian channels. Published specs: 4–20 cmH₂O, 28 dB, 1.49 kg, heated humidifier, detachable design, central-apnea detection, adaptive humidification, cloud connectivity. The algorithm is described in manufacturer brochures as advanced; the Indian service footprint is considerably thinner than ResMed or Philips. At this price, the AirSense 11 is the sharper buy for most patients.

Mid-tier (₹25,000–₹45,000)

The ResMed AirStart 10 Auto at ₹24,430 is ResMed’s entry-level APAP. Published specs: 4–20 cmH₂O, 26.6 dB, 1.1 kg, heated humidifier, SD card, EPR. It runs a standard-tier algorithm — not the AutoSet or AutoSet for Her platform — lacks heated-tube compatibility and lacks cloud connectivity by default. For a cost-constrained patient who wants ResMed build quality and the ResMed Indian service network, and does not need remote data monitoring, it is the entry point. Adherence outcomes with the AirStart are generally indistinguishable from the AirSense 10 in uncomplicated OSA, per published follow-up data.

The BPL Harmony Auto CPAP at ₹35,519 is the Indian-manufactured APAP from BPL (Bengaluru-headquartered). Published specs: 4–20 cmH₂O, 28 dB, 1.55 kg, heated humidifier, SD card, 2-year warranty. The turbine is a DC brushless motor with a claimed 20,000-hour service life per manufacturer brochure. Leak compensation is present; central-apnea detection and cloud connectivity are not. For patients who prioritize local-service reachability across non-metro India, BPL’s direct service footprint is one of the better ones in the mid-tier.

The Deckmount VT50 D Harmony (AFlex) Auto CPAP at ₹25,919 is an Indian-manufactured APAP with a claimed Made-in-India turbine. Published specs: 4–20 cmH₂O, 28 dB, 1.8 kg, heated humidifier, AFlex-style expiratory relief, SD card, QR-code data, SpO2-monitoring compatibility. The algorithm is standard-tier. The Deckmount value proposition is price and local service. The tradeoff is a thinner clinical data platform and a heavier unit.

The Oxymed SleepEasy AutoCPAP at ₹28,499 is an Indian-assembled APAP using a German turbine, per manufacturer brochure. Published specs: 4–20 cmH₂O, 30 dB, 2.0 kg, heated humidifier, adaptive humidification, central-apnea detection (FlowSens algorithm per manufacturer), leak compensation up to 60 L/min, cloud connectivity, 3-year warranty with PAN-India home service. The 3-year warranty with home service is genuinely differentiated in this price bracket; most mid-tier APAPs offer 2 years and expect the customer to ship the unit to the service centre. For tier-2 and tier-3 city buyers, this matters.

Budget tier (under ₹25,000)

The BMC RESmart GII Auto CPAP at ₹17,490 is the price-leader APAP in the Indian market. Published specs: 4–20 cmH₂O, 30 dB, 2.5 kg, heated humidifier, detachable design, SD card + iCode data, 2-year warranty. This is a standard-tier algorithm with no advanced event detection, no cloud connectivity, no heated-tube compatibility. It works — it auto-titrates within the prescribed window and records compliance data — but it does not deliver what the ResMed or Philips algorithms deliver. For a budget-constrained patient whose prescribing physician is comfortable managing them with SD-card data, or for a patient with mild OSA and no comorbidity, this is a defensible buy. For anyone with moderate-to-severe OSA or comorbidity, the pressure to step up to at least the AirStart 10 tier is real.

Travel APAPs (separate category)

The ResMed AirMini at ₹49,990 is the 300-gram travel APAP. Published specs: 4–20 cmH₂O, 27 dB, 0.3 kg, no built-in humidifier (uses HumidX waterless humidification inline), AutoSet and AutoSet for Her algorithms, Bluetooth to AirMini app, FAA-approved. It is a full-therapy APAP that happens to be tiny; it is not a step down in algorithm or efficacy. It is priced above most premium home APAPs because the engineering to hit that size without losing algorithm fidelity is non-trivial.

The Breas Z2 Auto at ₹62,687 is the Swedish-manufactured competitor in the travel category. Published specs: 4–20 cmH₂O, 26 dB, 0.299 kg, waterless humidification, Z-Breathe expiratory relief, Nitelog app via Bluetooth, optional PowerShell battery, FAA-approved. Algorithmically the Z2 is less sophisticated than the AirMini; the ergonomic and battery-integration design is comparable.

The BMC M1 Mini at ₹42,230 is the mid-priced travel APAP. Published specs: 4–20 cmH₂O, 30 dB, 0.4 kg, waterless humidification, Bluetooth to BMC companion app, three-level sensitivity (female/standard/soft). The sound level is noticeably higher than the AirMini or Z2, which matters in a hotel room or partner’s bedroom.

Indian pricing and procurement

APAP pricing in India in 2026 runs roughly: ₹17,000–₹30,000 budget tier (BMC RESmart GII, Deckmount VT50, Oxymed SleepEasy); ₹30,000–₹50,000 mid-tier (BPL Harmony, ResMed AirStart 10, BMC M1 Mini travel, Oxymed AirSmart); ₹50,000–₹80,000 premium (ResMed AirMini travel, Breas Z2 travel, ResMed AirSense 10 AutoSet, Wellel iX); ₹80,000–₹1,05,000 flagship (ResMed AirSense 11 AutoSet, top-tier Philips). GST at 12% applies to CPAP devices in the current schedule; customs duty is baked into premium-imported MRP.

Channel discounting is aggressive — a 30–45% discount on listed MRP is routine for ResMed, Philips, and Wellel devices, while Indian-manufactured devices (BPL, Deckmount, Oxymed) operate at 15–30% off MRP. Quoted current prices above are Indian e-commerce channel prices as observed; retail clinic pricing is typically 8–15% higher than online. Verify with the specific dealer at time of purchase — see our price tracker for more detail.

Maintenance, consumables, and service reality

An APAP is not a one-time purchase. Expect ₹3,000–₹6,000/year in consumables for mask cushions, tubing replacement, and filters. Humidifier chambers should be replaced every 6–12 months (₹1,500–₹3,500). Masks themselves typically last 6–12 months and cost ₹5,000–₹14,000 depending on type (pillows, nasal, full-face). Add a ₹800–₹2,000 servo-regulated voltage stabilizer to the setup — the grid-side voltage variance in much of India is outside the tolerance window of most imported APAPs, and a blown power supply on an out-of-warranty AirSense 11 can cost ₹18,000+ to replace.

Service-network depth is the single factor most patients underestimate at purchase. ResMed and Philips have authorized dealers in all Indian metros and most tier-2 cities; turnaround on a warranty repair is typically 7–14 days. BPL’s direct-owned service footprint is strong in South India, thinner in the North. Oxymed runs what it calls PAN-India home service on the 3-year warranty, which in practice varies by distance from the assembly base. BMC, Deckmount, and Wellel rely on the distributor channel; warranty turnaround can stretch to 3–4 weeks outside the major metros.

Final recommendation

For a patient presenting with moderate-to-severe OSA, no significant comorbidity, and a budget above ₹45,000, buy the ResMed AirSense 10 AutoSet or AirSense 11 AutoSet. The algorithm, the data ecosystem, and the service network together make this the default choice and the rest of the field is playing catch-up.

For budget-constrained patients, the Oxymed SleepEasy AutoCPAP at ₹28,499 with 3-year warranty and PAN-India home service is the sharpest buy under ₹30,000 — accepting that the algorithm is standard-tier and the clinical data platform is less developed than ResMed’s.

For patients who travel frequently and can justify a second device, the ResMed AirMini is the travel APAP to buy — full-therapy algorithm in 300 grams. If budget is tight, the BMC M1 Mini is adequate for the role.

For patients with central-apnea components, complex sleep apnea, hypoventilation, or any NIV indication, APAP is the wrong category — read our BiPAP ST, Auto BiPAP ST, or TVAPS guides instead.